- Trials with a EudraCT protocol (3,872)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (130)
3,872 result(s) found for: Product.
Displaying page 3 of 194.
EudraCT Number: 2008-007067-16 | Sponsor Protocol Number: TERJ001 | Start Date*: 2009-02-11 |
Sponsor Name:JELFA SA | ||
Full Title: Randomised, double-blind, parallel-group, comparative study of two terbinafine products | ||
Medical condition: tinea pedis (interdigital, Athlet´s foot) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001114-14 | Sponsor Protocol Number: ST261-DS-02-002 | Start Date*: 2004-10-22 |
Sponsor Name:SIGMA-TAU | ||
Full Title: BIOAVAILABILITY AND BIOEQUIVALENCE OF TWO ORAL FORMULATION OF L-PROPIONYLCARNITINE TABLET VS SACHET IN HEALTHY VOLUNTEERS AT THE DOSE OF 2 G OPEN, RANDOMISED, TWO-WAYS CROSS-OVER, SINGLE DOSE STUDY | ||
Medical condition: BIOEQUIVALENCE /BIOAVAILABILITY STUDY | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000061-11 | Sponsor Protocol Number: GAA 5233 | Start Date*: 2006-04-03 |
Sponsor Name:BODE Chemie GmbH & Co | ||
Full Title: Prospective randomized controlled double-blind multicentric phase III study to evaluate antiseptic efficacy and local tolerability of Stellisept mucosa in patients with chronic wounds | ||
Medical condition: ulcus cruris | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-003070-23 | Sponsor Protocol Number: CLITRETVER | Start Date*: 2023-01-27 | |||||||||||
Sponsor Name:Verisfield S.M.S.A. | |||||||||||||
Full Title: A multicenter, randomized, double-blind, parallel, three-arm, active- and placebo-controlled therapeutic equivalence for the comparison of clindamycin + tretinoin/Verisfield gel (1+0.025)% with Acn... | |||||||||||||
Medical condition: Acne Vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002987-27 | Sponsor Protocol Number: MEKOS 05 UseQ 001 | Start Date*: 2005-09-02 |
Sponsor Name:Mekos Laboratories | ||
Full Title: An open single centre evaluation of the reactivity of the T.R.U.E TestTM Quaternium-15 patch and a real use exposure in subjects known to be allergic to Quaternium-15. | ||
Medical condition: Diagnosis of Allergic Contact Dermatitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005584-24 | Sponsor Protocol Number: PREOB-NU3 | Start Date*: 2012-05-10 | |||||||||||
Sponsor Name:Bone Therapeutics S.A. | |||||||||||||
Full Title: A pivotal Phase IIb/III, multicentre, randomised, open, controlled study on the efficacy and safety of autologous osteoblastic cells (PREOB®) implantation in non-infected hypotrophic non-union frac... | |||||||||||||
Medical condition: Non-infected hypotrophic non-union fractures of long bones | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003387-27 | Sponsor Protocol Number: 848300145/0129/1POP04 | Start Date*: 2021-11-02 | ||||||||||||||||
Sponsor Name:Pharmaceutical Works Polpharma S.A. (Polpharma S. A.) | ||||||||||||||||||
Full Title: A PHASE III, MULTICENTRE, RANDOMISED, INVESTIGATOR-MASKED, CROSS-OVER, COMPARATIVE, NON-INFERIORITY TRIAL OF GENERIC LATANOPROST + TIMOLOL (50μG + 5MG)/ML EYE DROPS, SOLUTION (POLPHARMA S.A.) COMPA... | ||||||||||||||||||
Medical condition: Ocular hypertension and open angle glaucoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011785-28 | Sponsor Protocol Number: CEN BIOTECH 150309 | Start Date*: 2009-10-12 | |||||||||||
Sponsor Name:SUBSTIPHARM DEVELOPPEMENT | |||||||||||||
Full Title: Multicenter randomized, double blind, 3 parallel arms, controlled trial of the clinical efficacy of topical 'Diclofenac 1%, gel' (diclofenac diethylamine 1.16%) for the treatment of osteoarthritis ... | |||||||||||||
Medical condition: Patient présentant une ostéorthrose douloureuse d'au moins un des genoux. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011309-18 | Sponsor Protocol Number: R096769PRE4001 | Start Date*: 2009-12-02 | |||||||||||
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
Full Title: A Prospective, Observational Study of Men With Premature Ejaculation Who Are Treated With PRILIGY™ or Alternate Care | |||||||||||||
Medical condition: premature ejaculation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002913-37 | Sponsor Protocol Number: MPN-001-07-2018 | Start Date*: 2019-03-13 |
Sponsor Name:Antibiotic-Razgrad AD | ||
Full Title: Multicenter, prospective, randomized, double-blind, two-armed phase IV clinical study for efficacy and safety assessment of two 2% mupirocin containing nasal ointments (MupiroNasal 20mg/g, nasal oi... | ||
Medical condition: For elimination/eradication of nasal carriage of staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002784-25 | Sponsor Protocol Number: THO-IM_01-CT | Start Date*: 2013-10-04 | |||||||||||
Sponsor Name:Thrombotargets Europe | |||||||||||||
Full Title: A Phase II, randomized, controlled, double blind study to evaluate the haemostatic efficacy and safety of TT-173 applied in the donor site of patients undergoing skin graft. | |||||||||||||
Medical condition: Haemostatic effect in the donor site of patients undergoing skin graft. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000095-17 | Sponsor Protocol Number: HOLOGENE17 | Start Date*: 2017-08-17 |
Sponsor Name:Holostem Terapie Avanzate s.r.l. | ||
Full Title: PROSPECTIVE, OPEN-LABEL, UNCONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF AUTOLOGOUS CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED WITH A GAMMA-RETR... | ||
Medical condition: JEB is genetically and clinically heterogeneous characterized by mutations in COL17A1,encoding for Collagen17 protein. COLXVII is a collagenous transmembrane type II protein component of the hemide... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000722-30 | Sponsor Protocol Number: B0151005 | Start Date*: 2012-04-12 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A MULTICENTER OPEN-LABEL EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN STUDY B0151003 (ANDANTE II) | |||||||||||||
Medical condition: Crohn’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) GR (Prematurely Ended) BE (Completed) DK (Completed) HU (Completed) IT (Completed) CZ (Completed) AT (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023034-23 | Sponsor Protocol Number: B0151003 | Start Date*: 2011-06-03 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04236921 IN SUBJECTS WITH CROHN’S DISEASE WHO ARE ANTI-TNF INADEQUATE RESPONDERS (ANDANTE) | |||||||||||||
Medical condition: Crohn's Disease (active moderate to severe) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) HU (Completed) GB (Completed) GR (Completed) DK (Completed) DE (Completed) BE (Completed) IT (Completed) CZ (Completed) AT (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000331-63 | Sponsor Protocol Number: HGB-210 | Start Date*: 2021-02-09 | |||||||||||
Sponsor Name: bluebird bio, Inc. | |||||||||||||
Full Title: A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease. | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013326-17 | Sponsor Protocol Number: MI-CP208 | Start Date*: 2013-05-20 |
Sponsor Name:MedImmune, LLC | ||
Full Title: A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Children | ||
Medical condition: Prophylaxis of influenza | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2011-002341-35 | Sponsor Protocol Number: GA1103 | Start Date*: 2011-07-21 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd | ||
Full Title: A randomised single dose two cohort study comparing the speed of raft formation assessed by gamma scintigraphy in healthy volunteers following administration of a single dose of Gaviscon® Strawberr... | ||
Medical condition: To measure the formation and retention of alginate rafts in healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000517-33 | Sponsor Protocol Number: RP-L201-0318 | Start Date*: 2020-07-14 | |||||||||||
Sponsor Name:Rocket Pharmaceuticals, Inc. | |||||||||||||
Full Title: Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I):A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Len... | |||||||||||||
Medical condition: Leukocyte Adhesion Deficiency-I (LAD-I) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000481-38 | Sponsor Protocol Number: 161102 | Start Date*: 2012-06-28 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: Tolerability, Safety and Product Administration Evaluation of rHuPH20 Facilitated Subcutaneous Treatment with Immune Globulin (Human), 10% in Subjects with Primary Immunodeficiency Diseases – A Stu... | |||||||||||||
Medical condition: Primary Immunodeficiency Diseases | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001946-10 | Sponsor Protocol Number: E-RES/35/13-N08 | Start Date*: 2014-08-15 | |||||||||||
Sponsor Name:Cipla Ltd. | |||||||||||||
Full Title: A randomised, single dose, open label, two-period crossover study evaluating bioequivalence of salmeterol xinafoate HFA pMDI 25μg per actuation manufactured by Cipla Ltd, India (test product) with ... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
